United States In-Vitro Diagnostics Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

The Global In-Vitro Diagnostics market reached US$ 84.90 billion in 2024 and is expected to reach US$ 131.68 billion by 2032, growing at a CAGR of 5.0% during the forecast period 2025-2032.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/in-vitro-diagnostics-market?sb

In-Vitro Diagnostics Market report, published by DataM Intelligence has released its latest in-depth analysis on the global In-Vitro Diagnostics Market, delivering a detailed overview of regional growth patterns, market segmentation, CAGR, and financial performance among leading industry players. The report offers readers a clear snapshot of the current market value and volume, alongside an exploration of emerging opportunities and ongoing developments. By shining a spotlight on key market drivers and highlighting the evolving industry landscape, the report equips businesses and stakeholders with strategic insights to identify new growth avenues and navigate future market dynamics confidently.

Key Development:

United States: Recent Industry Developments
✅ In March 2026, Abbott announced expansion of its diagnostics portfolio following integration activities related to its planned acquisition of Exact Sciences to strengthen molecular and cancer testing capabilities. The move focuses on advanced screening and early disease detection technologies. It supports the company's strategy to expand precision diagnostics and oncology testing solutions.

✅ In February 2026, Roche launched new molecular and biomarker-based diagnostic tests including PCR and blood-based assays designed for infectious disease and neurological disorder detection. The new test portfolio targets faster and more accurate clinical decision-making in laboratories. It strengthens next-generation in-vitro diagnostic capabilities for high-complexity testing environments.

✅ In January 2026, the U.S. FDA updated regulatory guidance for digital health and clinical decision support technologies impacting diagnostic software and AI-based testing platforms. The revision aims to accelerate innovation while maintaining safety standards for medical devices. It supports faster development and approval of advanced diagnostic and in-vitro testing solutions.

✅ In October 2025, Blackstone and TPG agreed to acquire diagnostics company Hologic in a multi-billion-dollar deal to expand investment in women's health and molecular diagnostic technologies. The acquisition strengthens development of screening and infectious disease testing platforms. It highlights growing private investment in the in-vitro diagnostics sector.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=in-vitro-diagnostics-market

Japan: Recent Industry Developments

✅ In February 2026, Fujifilm launched advanced diagnostic and healthcare technology solutions including integrated diagnostic workflow systems designed to improve efficiency in clinical testing environments. The launch focuses on automation, imaging integration, and digital diagnostics platforms. It supports expansion of next-generation diagnostic infrastructure in hospitals and laboratories.

✅ In January 2026, H.U. Group subsidiary Fujirebio expanded its in-vitro diagnostics portfolio through development of biomarker-based testing reagents and automated analyzers used in clinical laboratories worldwide. The initiative focuses on neurological and oncology diagnostics. It strengthens Japan's position in high-precision IVD innovation.

✅ In July 2025, Japanese diagnostic manufacturers increased investment in molecular diagnostics and genetic testing technologies driven by demand for early disease detection and personalized medicine. The development includes expansion of PCR-based and immunoassay testing platforms. It supports long-term advancement of modern in-vitro diagnostic services.

✅ In April 2025, Roche collaborated with Japanese technology partners on AI-based companion diagnostic development for cancer detection using digital pathology and biomarker analysis. The system improves treatment selection through advanced data-driven diagnostics. It reflects rapid adoption of AI-enabled in-vitro diagnostic technologies in global healthcare.

Key Players:

=> BioMerieux, Becton, Dickinson and Company, Beckman Coulter, Inc, F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc, Abbott Laboratories, Qiagen NV, FUJIFILM Holdings Corporation, Sysmex Corporation and Siemens Healthineers AG among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/in-vitro-diagnostics-market?sb

Growth Forecast Projected:

The Global In-Vitro Diagnostics Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global In-Vitro Diagnostics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Key Segments:

➥ By Product Type: Instruments, Reagents, Software and Services, Others

➥ By Technique Type: Immunoassays, POC Diagnostics, Molecular Diagnostics, Hematology, Tissue Diagnostics, Microbiology, Self-Blood-Glucose Monitoring, Others

➥ By Application: Infectious Diseases, Diabetes, Oncology, Cardiology, Autoimmune Diseases, Nephrology, Drug Testing, Others

➥ By End-User: Diagnostic Laboratories, Hospitals, Academics and Research Institutes, Others

➥ By Region: North America, Latin America, Europe, Asia Pacific, Middle East, Africa

Regional Analysis for In-Vitro Diagnostics Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among In-Vitro Diagnostics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze In-Vitro Diagnostics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

FAQ

What is the current size of the In-Vitro Diagnostics Market?

A: In 2024, the In-Vitro Diagnostics Market was valued at US$ 84.90 billion, reflecting its strong industry presence.

Q2: How large is the In-Vitro Diagnostics Market expected to be by 2032?

A: By 2032, industry forecasts suggest the In-Vitro Diagnostics Market will grow to around US$ 131.68 billion, demonstrating significant expansion.

Q3: What is the growth rate of the In-Vitro Diagnostics Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 5.0% during the forecast period from 2025 to 2032.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.